Dr. Marshall A. Mazepa, MD

Dr. Mazepa practices at M Health Fairview University of Minnesota Medical Center in Minneapolis, Minnesota, part of M Health Fairview.

Dr. Mazepa's NPI, 1174569354, was assigned on June 22, 2006. Dr. Mazepa graduated from University of Wisconsin School of Medicine in 2006. Dr. Mazepa holds North Carolina license 157749.

Dr. Mazepa's primary practice is M Health Fairview University of Minnesota Medical Center, at 2450 Riverside Avenue, Minneapolis, MN 55454 in Hennepin County. The practice phone is (612) 624-1765.

Dr. Mazepa's primary practice is M Health Fairview University of Minnesota Medical Center in Minneapolis, Minnesota, part of M Health Fairview. Dr. Mazepa is also affiliated with M Health Fairview Southdale Hospital. The medical group on file is M Health Fairview Recovery Clinic. Dmand AI also links Dr. Mazepa to 3 more hospitals, 4 medical groups and 1 dialysis center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mazepa practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Mazepa's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Mazepa is board certified in hematology by the American Board of Internal Medicine. Dr. Mazepa is licensed in North Carolina.

CMS data shows 73 Medicare services from Dr. Mazepa across 5 procedure codes in 2024, for 92 Medicare patients. Medicare paid $5,596 for them.

CMS counts 92 Medicare patients who saw Dr. Mazepa in 2024. The largest group is 65 to 74, with 34 patients. 70% of them have high blood pressure, and 55% have high cholesterol. 39% are also on Medicaid. Their average risk score is 3.34, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mazepa's median patient age at 61, with 52% women.

In 2024, Dr. Mazepa wrote 571 Medicare Part D claims for 77 patients. 44% of them were for generic drugs. CMS names the drug for 445 of them, across 15 drugs with 11 or more claims each, at $1,276,403 in total drug cost. In 2023, CMS named 355 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Mazepa for performance year 2024, reported as part of a group. Dr. Mazepa accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mazepa as offering telehealth.

Dmand AI links 43 papers to Dr. Mazepa, published from 2013 to 2025. 2019 was the busiest year, with 4. The most frequent topics are Purpura, Thrombotic Thrombocytopenic, ADAMTS13 Protein and Plasma Exchange. Dr. Mazepa has published most often in Am J Hematol. Dr. Mazepa's most frequent co-authors are Shruti Chaturvedi, MD, Spero R. Cataland, MD and Raj S. Kasthuri, MBBS, MD.

Dmand AI links Dr. Mazepa to 1 clinical trial. Open Payments lists research payments to Dr. Mazepa that name 1 trial.

CMS Open Payments shows 6 general payments to Dr. Mazepa from 3 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 93% of the total. Novartis Pharmaceuticals Corporation paid the most, $6,901. It also lists 7 research payments totaling $55,055 from 2024 to 2025, naming 1 clinical trial.

Dr. Mazepa graduated from University of Wisconsin School of Medicine in 2006.